Latest Period
Q2 2026
Security Snapshot
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) Institutional Ownership
CUSIP: 457637700
13F Institutional Holders and Ownership History from Q4 2024 to Q2 2026
Institutions Reporting
20
Shares (Excl. Options)
2,697,637
Price
$1.55
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, no par value
- Symbol
- INM on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,697,637
- Total 13F value
- $5,181,329
- Portfolio coverage rank
- 0%
- Share change
- +2,378,336
- Value change
- +$4,711,680
- Number of holders
- 20
- Shares outstanding
- 3,277,000
- SEC-reported price per share
- $1.44
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- INM - InMed Pharmaceuticals Inc. - Common Shares, no par value is tracked under CUSIP 457637700.
- 20 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 8 to 20 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $206,034 to $5,181,329.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 20 institutions filings for Q2 2026.
Security key
457637700
Latest holder period
Q2 2026
13F holders
20
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
INM full holder history
InMed Pharmaceuticals Inc. SEC filings
InMed Pharmaceuticals Inc. company facts
InMed Pharmaceuticals Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 457637700:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
INM
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 24% | $512,000 | 800,000 | ADAR1 Capital Management, LLC | 31 May 2026 | |||
| Vivo Opportunity Fund Holdings, L.P. | 22% | $459,804 | 718,444 | Vivo Opportunity Fund Holdings, L.P. | 19 May 2026 | |||
| Squadron Capital Management LLC | 9.8% | $208,000 | 325,000 | Squadron Master Fund LP | 19 May 2026 | |||
| SABBY MANAGEMENT, LLC | 9.9% | $333,364 | 280,138 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | |||
| Ikarian Capital, LLC | 4.2% | $221,591 | 137,634 | Ikarian Capital, LLC | 30 Jun 2026 |
As of 30 Jun 2026, 20 institutional investors reported holding 2,697,637 shares of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM). This represents 82% of the company’s total 3,277,000 outstanding shares.
13F concentration
Top 22 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
82%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 24% | 800,000 | 0.06% | $1,240,000 | |
| Vivo Capital, LLC | 24% | 798,377 | 0.11% | $1,237,484 | |
| Squadron Capital Management LLC | 9.9% | 325,000 | 0.17% | $503,750 | |
| Ikarian Capital, LLC | 7.5% | 245,025 | 0.06% | $379,788 | |
| Ursa Fund Management, LLC | 3.8% | 125,800 | 0.03% | $194,990 | |
| MONTANOVA CAPITAL, LLC | 3.1% | 100,000 | 0% | $155,000 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 2.3% | 74,244 | 0% | $115,078 | |
| SABBY MANAGEMENT, LLC | 1.4% | 44,970 | -80% | 0.58% | $69,704 |
| JANE STREET GROUP, LLC | 1.3% | 43,078 | 0% | $66,771 | |
| Venrock Adviser, LLC | 1% | 32,685 | 0% | $50,662 | |
| CITADEL ADVISORS LLC | 0.8% | 26,084 | -44% | 0% | $40,430 |
| SEVEN GRAND MANAGERS, LLC | 0.76% | 25,000 | 0% | $38,750 | |
| Scientech Research LLC | 0.47% | 15,461 | 0.02% | $23,965 | |
| Crestwood Advisors Group, LLC | 0.45% | 14,900 | 0% | $23,095 | |
| TWO SIGMA SECURITIES, LLC | 0.33% | 10,945 | -42% | 0% | $16,965 |
| Stratos Wealth Partners, LTD. | 0.33% | 10,760 | 0% | $16,678 | |
| Private Wealth Management Group, LLC | 0.15% | 5,000 | 0% | 0% | $7,750 |
| SBI Securities Co., Ltd. | 0.01% | 300 | 0% | 0% | $465 |
| Banque Cantonale Vaudoise | 0% | 6 | 0.04% | $1,000,000 | |
| Federation des caisses Desjardins du Quebec | 0% | 2 | 0% | 0% | $4 |
| Virtu Financial LLC | 0% | 0 | -100% | $0 | |
| UBS Group AG | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q2 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 2,697,637 | $5,181,329 | +$4,711,680 | $1.55 | 20 |
| 2026 Q1 | 319,301 | $206,034 | +$49,348 | $0.64 | 8 |
| 2025 Q4 | 227,043 | $240,666 | -$175,633 | $1.06 | 6 |
| 2025 Q3 | 303,584 | $665,240 | +$637,052 | $2.19 | 8 |
| 2025 Q2 | 8,470 | $28,508 | +$7,682 | $3.25 | 6 |
| 2025 Q1 | 6,408 | $13,264 | -$185,585 | $2.04 | 4 |
| 2024 Q4 | 48,870 | $226,645 | +$226,645 | $4.87 | 4 |